Trials / Completed
CompletedNCT02969018
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06700841 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2016-11-21
- Last updated
- 2019-03-29
- Results posted
- 2019-03-29
Locations
44 sites across 3 countries: United States, Canada, Poland
Source: ClinicalTrials.gov record NCT02969018. Inclusion in this directory is not an endorsement.